Related Experiment Video

Updated: Jun 22, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Development of IGF-IR Inhibitors in Pediatric Sarcomas

E Anders Kolb1, Richard Gorlick

  • 1Alfred I. duPont Hospital for Children, Nemours Center for Childhood Cancer Research, 1600 Rockland Road, Wilmington, DE 19803, USA. eakolb@nemours.org

Current Oncology Reports
|June 11, 2009
PubMed

Insights

Insulin-like growth factor (IGF) therapies show promise for pediatric sarcomas like osteosarcoma and Ewing sarcoma. Ongoing clinical trials are exploring these IGF-targeted drugs, overcoming past toxicity limitations.

Area of Science:

  • Pediatric Oncology
  • Molecular Targeted Therapy
  • Cancer Biology

Background:

  • Insulin-like growth factor (IGF) has been linked to pediatric cancers (osteosarcoma, Ewing sarcoma, rhabdomyosarcoma) for 20 years.
  • Previous IGF-targeted therapies faced significant toxicity, hindering clinical progress.
  • New, specific small molecules and antibodies targeting the IGF-I receptor offer renewed therapeutic potential.

Purpose of the Study:

  • To review preclinical data on IGF-targeted inhibitors in pediatric sarcomas.
  • To discuss ongoing clinical trials for these novel therapies.
  • To address challenges in developing IGF-targeted drugs for pediatric malignancies.

Main Methods:

  • Review of preclinical studies using IGF-I receptor inhibitors in pediatric sarcoma xenograft models.
  • Analysis of clinical trial data, including responses in adult Ewing sarcoma patients.
  • Examination of safety profiles and toxicity data from early-phase trials.

Main Results:

  • Preclinical data demonstrate efficacy of IGF-I receptor inhibitors against pediatric sarcoma models.
  • Positive responses observed in adult Ewing sarcoma patients suggest potential in pediatric populations.
  • Development of more specific IGF-targeted agents has reduced toxicity concerns.

Conclusions:

  • IGF-targeted therapies, particularly those inhibiting the IGF-I receptor, represent a promising avenue for pediatric sarcoma treatment.
  • Ongoing clinical trials are crucial for validating the efficacy and safety of these agents in children.
  • Further research is needed to optimize drug development and overcome specific challenges in pediatric oncology.

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...